A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05318976 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Mild Cognitive Impairment

Interventions

DRUG: XPro1595
DRUG: Placebo

Sponsor

Inmune Bio, Inc.